82. Metastatic triple-negative breast cancer (TNBC)

Oncology for the Inquisitive Mind would like to issue a formal mae culpa to our listeners. You have joined us for over 12 months and over 80 episodes and listened to our ramblings and bad jokes. And it has taken 80 episodes for us to realise we have neglected the crucial and exciting subject of metastatic triple-negative breast cancer (TNBC). But fear not! We will rectify this egregious oversight with immediate effect. TNBC remains the scourge of the usually more optimistic breast cancer space. However, the fight of the world's oncologists continues across all fronts, and TNBC is no different. In today's episode, Michael and Josh will discuss the twin pillars of modern anti-cancer therapies: antibody-drug conjugates (sacituzumab govitecan) and immunotherapy (pembrolizumab). As so often the case, this is a growth area of medical oncology and one that we are very excited to (finally) address.
Links to studies discussed in this episode (subscription may be required):
ASCENT: www.nejm.org/d...
KEYNOTE-355: www.nejm.org/d...

[@venkatgill]

Hi - while going through adjuvant chemo of Pembro + capecetabine - diagnosed with bone metastases in 6 month PET scan. Surgery was in May'23. Metastasis in 7 months. Doctors advised to start treatment with SG (Trodelvy) alone. No other combination therapies suggested. Originally PD-L1 score was 1.
Do you recommend single agent SG or combination of agents for better results this time around? Age is 36 and as discussed in this video, may be able to tolerate combination therapies.